TY - JOUR
T1 - Inhibition of Exercise-Induced Bronchoconstriction by MK-571, a Potent Leukotriene D4–Receptor Antagonist
AU - Amirav, Israel
AU - Pawlowski, Nicholas
AU - Manning, P. J.
AU - Watson, R. M.
AU - Margolskee, D. J.
AU - Williams, V. C.
AU - Schwartz, J. I.
AU - O'byrne, P. M.
PY - 1991/5/2
Y1 - 1991/5/2
N2 - To the Editor: Manning et al. (Dec. 20 issue)1 elegantly demonstrated that pretreatment with MK-571, a selective leukotriene D4—receptor antagonist, markedly attenuated exercise-induced bronchoconstriction in patients with asthma. However, we have some reservations about their methods. The authors claim that treatment with MK-571 afforded almost complete protection in 5 of the 12 subjects (Subjects 2, 3, 4, 6, and 8) studied. However, except for Subject 3, the importance of the protection in these subjects may be questioned. The degree of exercise-induced bronchoconstriction in these four subjects during both the placebo and active-drug phases was less than 15.
AB - To the Editor: Manning et al. (Dec. 20 issue)1 elegantly demonstrated that pretreatment with MK-571, a selective leukotriene D4—receptor antagonist, markedly attenuated exercise-induced bronchoconstriction in patients with asthma. However, we have some reservations about their methods. The authors claim that treatment with MK-571 afforded almost complete protection in 5 of the 12 subjects (Subjects 2, 3, 4, 6, and 8) studied. However, except for Subject 3, the importance of the protection in these subjects may be questioned. The degree of exercise-induced bronchoconstriction in these four subjects during both the placebo and active-drug phases was less than 15.
UR - http://www.scopus.com/inward/record.url?scp=0025865136&partnerID=8YFLogxK
U2 - 10.1056/nejm199105023241815
DO - 10.1056/nejm199105023241815
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???
C2 - 1849613
AN - SCOPUS:0025865136
SN - 0028-4793
VL - 324
SP - 1288
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 18
ER -